- The P-III (NCT02524847) study involves assessing of Therakos + methoxsalene in 25 pediatric patients with aGvHD aged 1 yr to 21 yrs. @4,12 wks.
- The P-III study resulted in general response rates @4,12 wks. (74%, 48%,) with OR exceeding the target rates in mid-term study
- Therakos Immunotherapy is delivered using CELLEX system for the treatment of skin manifestations in CTCL used in almost 25 countries
Click here to read full press release/ article | Ref: PRNewsWire | Image: WSJ